DOTmed Home MRI Oncology Ultrasound Molecular Imaging X-Ray Cardiology Health IT Business Affairs
News Home Parts & Service Operating Room CT Women's Health Proton Therapy Endoscopy HTMs Mobile Imaging
SEARCH
Ubicación actual:
>
> This Story


Conexión o Registro to rate this News Story
Forward Printable StoryPrint Comment

 

Women's Health Homepage

New machine learning tool identifies breast lesions likely to become cancerous May help reduce unnecessary surgical procedures

Hypofractionated whole-breast radiotherapy best for early-stage breast cancer patients under 50 Study supports higher dose, shorter form treatment

Study finds mobile mammo patients aren't getting the follow-up imaging they need Socioeconomic factors credited for low adherence rates

Hologic launches SmartCurve breast stabilization system for U.S. consumers A more comfortable mammogram without compromised image quality

Survey finds radiation therapy isn't as scary as it seems Many patients unaware of major technological advances

New MR contrast agent distinguishes aggressive from slow-growing breast cancer Lights up biomarkers in different shades of brightness

Study finds MR detects 98 percent of pregnancy-related breast cancers May also inform surgical management of disease

Hologic introduces its 3Dimensions mammo system to the European market Improvements in accuracy, clarity, workflow and dose

Hologic launches Brevera breast biopsy system in the U.S. Doctors can perform and examine biopsy results in the same room

Rhonda Engebretson ASRT member selected for FDA Mammography Quality Assurance Committee

The TMIST study will determine if 3-D
mammograms reduce a woman's risk of
developing life-threatening cancer
than 2-D mammograms

Researchers to assess benefits of 3-D mammo versus 2-D

por John Fischer , Staff Reporter
A new study could determine if 3-D mammography reduces a woman’s risk of developing life-threatening breast cancer more than 2-D.

The ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) and the National Cancer Institute (NCI) have developed the Tomosynthesis Mammographic Imaging Screening Trial (TMIST) to compare the two types of digital mammography in breast cancer screenings. ECOG-ACRIN will lead the study.

Story Continues Below Advertisement

qualiTEE - reliabiliTEE - repairabiliTEE - we guaranTEE

Bayer HealthCare Multi Vendor Service will repair your transducer with the same precision and care you provide to your patients. Now offering TotalREPAIR on 140 transducer models! Call us at 1-844-5100 or visit www.mvs.bayer.com to set up an order today.



“The information related to detecting life-threatening cancers is important because it gets to the purpose and essence of cancer screening,” Dr. Worta McCaskill-Stevens, M.D., M.S., chief of the Community Oncology and Prevention Trials Research Group at NCI, told HCB News. ”Another important aspect is that TMIST will compare the benefits and harms between 2-D and 3-D.”

3-D mammography is likely to detect more findings that require follow-ups and lead to more procedures and treatments than 2-D. It is unknown whether 3-D is better able to reduce a woman’s risk of developing an advanced, life-threatening form of cancer.

The trial will follow 165,000 women between 45 and 74 who are planning to undergo routine mammograms. Researchers will use the findings to determine the best course of action for screening women, as well as how to help women make informed decisions regarding screenings.

Participants will each be assigned to undergo either 3-D or 2-D mammogram screenings. Most will be screened annually. Postmenopausal women who show no high risk factors will be screened every two years. The study will also take into account diversity, basing participants on geographic location sites, race and ethnicity.

Data from each mammogram will be collected and evaluated, including imaging that shows no signs, suspicion or diagnosis of breast cancer. Follow-ups for imaging and biopsies will be reported. All participants will be checked for breast cancer status, treatment and outcomes from the time each starts the trial through at least 2025. Women who are diagnosed with breast cancer during any part of the study will continue to be a part of it and receive treatment.

All participants are encouraged to voluntarily submit blood samples and a swab of buccal cells from inside the mouth as part of TMIST’s effort to create a biorepository for future genetic markers for breast cancer. This will enable doctors and women to determine the best methods for screenings and evaluate risk factors of individual patients for developing diseases.

Tissue will also be collected from women who undergo biopsies as part of follow-ups for mammogram findings, allowing TMIST researchers to study the biology of screen-detected abnormalities and to evaluate the overdiagnosis of breast cancer from screenings.
  Pages: 1 - 2 >>

Women's Health Homepage


You Must Be Logged In To Post A Comment

Anuncie
Aumente su conciencia de marca
Subastas + ventas Privadas
Consigue el mejor precio
Comprar Equipo/Piezas
Encuentra El Precio Más Bajo
Noticias diarias
Lee las últimas noticias
Directorio
Examina todos los usuarios DOTmed
Ética en DOTmed
Ver nuestro programa de ética
El oro parte programa del vendedor
Recibir las solicitudes de PH
Programa de distribuidor con servicio gold
Recibe solicitudes
Proveedores de atención de salud
Ver todos los HCP (abreviatura de asistencia médica) Herramientas
Trabajos/Entrenamiento
Encontrar/rellenar un trabajo
Parts Hunter +EasyPay
Obtener presupuestos para piezas
Certificado recientemente
Ver usuarios certificados recientemente
Recientemente clasificado
Ver usuarios certificados recientemente
Central de alquiler
Alquila equipos por menos
Vende equipos/piezas
Obtén más dinero
Mantenga el foro de los técnicos
Buscar ayuda y asesoramiento
Petición sencilla de propuestas
Obtén presupuestos para equipos
Feria comercial virtual
Encuentra servicio para el equipo
El acceso y el uso de este sitio está conforme a los términos y a las condiciones de nuestro AVISO LEGAL & AVISO DE LA AISLAMIENTO
Característica de y propietario DOTmeda .com, inc. Copyright ©2001-2017 DOTmed.com, Inc.
TODOS LOS DERECHOS RESERVADOS